Rezolute is a clinical stage biopharmaceutical company dedicated to developing transformative therapies for patients suffering from debilitating metabolic diseases.
Congenital hyperinsulinism (HI) is a rare genetic disease that presents very early in life and is characterized by excess and erratic insulin secretion that can cause infants, children, and adults to become dangerously hypoglycemic and starve their bodies of glucose.
Diabetic Macular Edema (DME) is a disease associated with diabetes, when chronic excess glucose in the blood stream can cause inflammation and breakdown of the body’s blood vessels , including at the back of the eye where fluid may leak into the retina. DME is the leading cause of blindness in the US and elsewhere.
We are committed to responding to the needs of patients, caregivers, and medical professionals by addressing the shortcomings of current standards of care. We develop therapies that we believe have the potential to transform the treatment paradigm and significantly improve clinical outcomes as well as the quality of life for patients and their families.